Drug Description in Trials / DrugBank / KEGG DRUG


Search results


No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1ANTI-VON willebrand factor nanobody, caplacizumab
(D11160)
----[1] 64 💬
2ANTI-VON willebrand factor nanobody, INN = caplacizumab
(D11160)
[1] Caplacizumab[1] Caplacizumab (D11160) 💬 [1] VWF 💬 [8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬[1] 64 💬
3Caplacizumab
(D11160)
[1] Caplacizumab[1] Caplacizumab (D11160) 💬 [1] VWF 💬 [8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬[2] 63, 64 💬